In its latest report, the Institute for Clinical and Economic Review (ICER) evaluated the efficacy and value of newer targeted agents that treat moderate-to-severe plaque psoriasis compared with non-targeted therapies.
Most notably, treatments guselkumab (Tremfya, Johnson & Johnson) and risankizumab (AbbVie) succeeded in demonstrating greater clinical benefit when compared with non-targeted therapies, according to ICER.
At a public meeting, the ICER received input from members of the New England Comparative Effectiveness Public Advisory Council, one of ICER’s 3 independent evidence appraisal committees, based on newly incorporated clinical data and cost information. The updated report, which adds to the 2016 findings, includes recently-approved drugs and risankizumab, which was filed with the FDA for review in April 2018.
Council members further voted that evidence was not adequate to show a net health benefit of tildrakizumab (Ilumya, Sun Pharma/Merck) compared with TNFα inhibitors or the TNFα inhibitor certolizumab pegol over the other subcutaneously-administered TNFα inhibitors (adalimumab and etanercept).

Click to continue reading on Specialty Pharmacy Times.